Aditxt Inc. Cash Flow Conversion Efficiency
Aditxt Inc. cash flow conversion efficiency. Based on the latest financial reports, Aditxt Inc. (ADTX) has a cash flow conversion efficiency ratio of 0.130x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.58 Million) by net assets ($-35.17 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Aditxt Inc. (2017–2025)
Cash flow conversion efficiency of Aditxt Inc. from 2017 to 2025. This chart illustrates how Aditxt Inc. 's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Aditxt Inc. stock quote for real-time trading data and today's change.
Aditxt Inc. Cash Flow Conversion Ratio Explained
Aditxt Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Aditxt Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aditxt Inc. ranked by their cash flow conversion efficiency. Also see ADTX market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Abpro Holdings, Inc.
NYSE:ABP
|
0.146x |
|
Renold
LSE:RNO
|
0.166x |
|
Ganga Forging Limited
NSE:GANGAFORGE
|
0.016x |
|
East Coast Furnitech Public Company Limited
BK:ECF
|
-0.159x |
|
Playgon Games Inc
V:DEAL
|
0.038x |
|
Amatheon Agri Holding NV
PA:MLAAH
|
-0.204x |
|
UTime Limited
NASDAQ:WTO
|
0.019x |
|
CirChem AB
ST:CIRCHE
|
-0.143x |
Annual Cash Flow Conversion Efficiency for Aditxt Inc. (2017–2025)
The table below shows the annual cash flow conversion efficiency of Aditxt Inc. from 2017 to 2025. Review ADTX FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $3.95 Million | $-25.69 Billion | -6497.326x | -321096.90% |
| 2024-12-31 | $8.29 Million | $-16.76 Million | -2.023x | -74.73% |
| 2023-12-31 | $16.05 Million | $-18.58 Million | -1.158x | +73.08% |
| 2022-12-31 | $5.21 Million | $-22.39 Million | -4.301x | -96.55% |
| 2021-12-31 | $10.18 Million | $-22.28 Million | -2.188x | -233.69% |
| 2020-12-31 | $11.01 Million | $-7.22 Million | -0.656x | -502.79% |
| 2019-12-31 | $-2.85 Million | $-464.35K | 0.163x | -35.23% |
| 2018-12-31 | $-1.54 Million | $-386.26K | 0.251x | -96.10% |
| 2017-12-31 | $-59.90K | $-386.26K | 6.448x | -- |
About Aditxt Inc.
Aditxt, Inc. focuses on discovery and development of biopharmaceutical products. The company develops AditxtScore and FlowSpot that enable individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body nat… Read more